Tempus
Founded Year
2015Stage
IPO | IPOTotal Raised
$1.345BDate of IPO
6/14/2024Market Cap
7.92BStock Price
44.62Revenue
$0000About Tempus
Tempus specializes in AI-enabled patient care solutions focusing on integrating artificial intelligence with healthcare to provide personalized treatment options. It offers services such as genomic profiling, algorithmic tests, and clinical trial matching, which leverage large libraries of clinical and molecular data to support data-driven decisions for personalized patient care. It was formerly known as Tempus Consulting. The company was founded in 2015 and is based in Chicago, Illinois.
Loading...
ESPs containing Tempus
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The real-world data providers market offers a variety of value propositions to the pharmaceutical industry, drug labs, and healthcare organizations. It provides access to diverse patient populations, longitudinal real-world data, and patient-powered or EHR-powered controls that can replicate real-world scenarios. This can help shorten drug development timelines, reduce patient recruitment burdens …
Tempus named as Leader among 15 other companies, including Syapse, TriNetX, and ConcertAI.
Tempus's Products & Differentiators
Sequencing
Use our genomic platform to prospectively sequence through clinical trials and retrospectively support research priorities
Loading...
Research containing Tempus
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Tempus in 18 CB Insights research briefs, most recently on Oct 3, 2024.
Oct 3, 2024 report
State of Venture Q3’24 Report
Aug 21, 2024
The clinical trials tech market map
Jul 18, 2024 report
State of Digital Health Q2’24 Report
Jul 3, 2024 report
State of Venture Q2’24 Report
Aug 29, 2023
The pharma AI market mapExpert Collections containing Tempus
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Tempus is included in 9 Expert Collections, including AI 100.
AI 100
99 items
Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.
Conference Exhibitors
5,501 items
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
Digital Health 50
300 items
The most promising digital health startups transforming the healthcare industry
Digital Health
11,109 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Tempus Patents
Tempus has filed 146 patents.
The 3 most popular patent topics include:
- molecular biology
- oncology
- genetics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/12/2022 | 10/29/2024 | Immune system, Immunology, Clusters of differentiation, T cells, Transcription factors | Grant |
Application Date | 8/12/2022 |
|---|---|
Grant Date | 10/29/2024 |
Title | |
Related Topics | Immune system, Immunology, Clusters of differentiation, T cells, Transcription factors |
Status | Grant |
Latest Tempus News
Oct 31, 2024
Tempus AI (TEM) Set to Announce Earnings on Thursday Posted by MarketBeat News on Oct 31st, 2024 Tempus AI ( NASDAQ:TEM – Get Free Report ) is scheduled to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Tempus AI to post earnings of ($0.27) per share for the quarter. Tempus AI has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link . Tempus AI ( NASDAQ:TEM – Get Free Report ) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($6.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.41) by ($2.36). The business had revenue of $165.97 million for the quarter, compared to analysts’ expectations of $159.10 million. On average, analysts expect Tempus AI to post $-7 EPS for the current fiscal year and $-1 EPS for the next fiscal year. Get Tempus AI alerts: Tempus AI Price Performance Tempus AI stock opened at $45.51 on Thursday. The stock has a fifty day simple moving average of $51.99. Tempus AI has a 52-week low of $22.89 and a 52-week high of $77.00. The company has a quick ratio of 3.52, a current ratio of 3.70 and a debt-to-equity ratio of 4.50. Analyst Upgrades and Downgrades A number of equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Tempus AI from $42.00 to $47.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Piper Sandler started coverage on shares of Tempus AI in a research report on Monday, August 12th. They issued a “neutral” rating and a $40.00 price objective for the company. Longbow Research assumed coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They set a “buy” rating and a $48.00 target price on the stock. Morgan Stanley started coverage on shares of Tempus AI in a report on Tuesday, July 9th. They set an “overweight” rating and a $44.00 price target for the company. Finally, Bank of America lowered shares of Tempus AI from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $45.00 to $60.00 in a report on Wednesday, October 2nd. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and an average target price of $48.67.
Tempus Frequently Asked Questions (FAQ)
When was Tempus founded?
Tempus was founded in 2015.
Where is Tempus's headquarters?
Tempus's headquarters is located at 600 West Chicago Avenue, Chicago.
What is Tempus's latest funding round?
Tempus's latest funding round is IPO.
How much did Tempus raise?
Tempus raised a total of $1.345B.
Who are the investors of Tempus?
Investors of Tempus include Ares Management, T. Rowe Price, Scottish Mortgage Investment Trust, Franklin Venture Partners, Novo Holdings and 8 more.
Who are Tempus's competitors?
Competitors of Tempus include AnchorDx, Molecular You, Atropos Health, Genetron Health, Zephyr AI and 7 more.
What products does Tempus offer?
Tempus's products include Sequencing and 4 more.
Who are Tempus's customers?
Customers of Tempus include AstraZeneca, GSK, Genmab and Bayer.
Loading...
Compare Tempus to Competitors
Aetion operates as a healthcare analytics company. It provides decision-grade real-world evidence solutions to biopharma companies, payers, and regulatory agencies. It offers a platform that analyzes data from the real world to produce scientifically validated answers on treatments, effectiveness, and value. The company was founded in 2012 and is based in New York, New York.
Owkin operates as an artificial intelligence (AI)-based biotechnology company. It utilizes AI to enhance the process of finding suitable treatments for patients. The company's main services include the use of AI to identify new treatments, accelerate clinical trials, and build diagnostic tools. It enables researchers in hospitals, universities, and the biopharmaceutical industry to understand how drug efficacy varies for the improvement of drug development. Its services primarily cater to the biopharmaceutical and academic research sectors. It was founded in 2016 and is based in New York, New York.
ConcertAI is a leader in clinical artificial intelligence and real-world data products within the healthcare sector. The company offers a suite of AI-driven solutions and services designed to optimize clinical trials, provide predictive patient insights, and support commercial healthcare solutions. ConcertAI primarily serves the oncology research and clinical development sectors. It was founded in 2017 and is based in Cambridge, Massachusetts.
Caris focuses on molecular science, specifically in the domain of cancer care. The company offers services such as molecular profiling, blood profiling, and tissue profiling, which provide comprehensive molecular information to help oncologists create personalized treatment plans for cancer patients. It primarily sells to the healthcare industry, particularly oncology. It was founded in 1996 and is based in Irving, Texas.
Syapse focuses on transforming real-world evidence into actionable insights within the healthcare sector. The company empowers healthcare organizations to collaborate and deliver patient insights to improve care, particularly for cancer patients. Syapse's services are primarily utilized by healthcare providers and organizations seeking to enhance patient outcomes through data-driven insights. Syapse was formerly known as BDLicense. It was founded in 2008 and is based in San Francisco, California.
TriNetX operates in the life sciences and healthcare sectors, focusing on the utilization of real-world data. The platform offered by the company allows access to de-identified patient records, datasets, and consulting services, enabling users to optimize protocol design, simplify trial operations, refine safety signals, and generate real-world evidence. Its primary customers are healthcare organizations and life sciences companies. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Loading...